anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study aimed to determine the occurrence of incidental obturator hernia and clinical risk factors of their appearance in patients undergoing totally extraperitoneal (TEP) inguinal hernioplasty.
METHODS: Data were collected retrospectively from patients who underwent TEP inguinal hernioplasty between June 2020 and December 2022.
RESULTS: A total of 251 patients were included in the study. Obturator hernias were found in 21 patients (8.4%). At admission, no patient presented clinical signs of an obturator hernia. There was a significant predominance of women in the obturator hernia compared to the non-obturator hernia group (28.6% vs. 10.9%, respectively, p=0.018). There was no correlation between age (p=0.479) and BMI (p=0.771) and the occurrence of obturator hernia. Additional obturator hernia repair within the TEP inguinal hernioplasty procedure did not influence the overall length of the surgery (60.86 minutes) compared to the standard TEP inguinal hernioplasty (61.09 minutes, p=0.876).
CONCLUSIONS: The TEP inguinal hernioplasty allows the detection and repair of incidental obturator hernia. Through thorough inspection of the obturator canal, an asymptomatic obturator hernia can be detected and adequately treated within the same procedure, without the impact on the surgery duration, when performed by an experienced hernia surgeon.
THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydrOXYzine their dosage should be reduced.

Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydrOXYzine. Patients should also be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.

A determination has not been made whether controlled clinical studies of hydrOXYzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. Geriatric Use:

The extent of renal excretion of hydrOXYzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydrOXYzine and observed closely.
Intrauterine adhesions (IUA) occurred in the reproductive-age women are a big economic and health problem, resulting in severe impairment of social, psychological and physical function of the female genital organs. IUA-related symptoms or signs are varied greatly from free of symptoms or ambiguous symptoms (an incidental finding during the intervention) to ceased menstruation and loss of fecundability. The underlying pathophysiology is not completely understood, but intrauterine damage with broken basal layers of the endometrium formatting scar tissues or fibrosis in the endometrium with subsequently causing partial or complete occlusion of the uterine cavity may be a well-accepted hypothesis. Previously, infection is the most common cause to develop IUA, but now, intrauterine surgery may be a critical cause contributing to the majority of cases of IUA. In the current review, update information about the etiology, epidemiology, pathophysiology, sequelae and prevention of IUA will be renewed. We emphasize the importance of awareness of IUA, and primary prevention should be considered in the routine clinical practice if intrauterine surgery has been applied, based on uncertainty of ideal treatment for the established IUA and unpredictable outcomes after IUA treatment. So far, evidence supports that hyaluronic acid with/without other strategy is the most valuable and effective method to reduce the formation and re-formation of IUA as well as to achieve the best fertility outcome.
Intravenous administration or unintentional intravascular injection during epidural administration of Sufentanil Citrate Injection may cause muscle rigidity, particularly involving the muscles of respiration. The incidence and severity of muscle rigidity is dose related. These effects are related to the dose and speed of injection. Administration of sufentanil may produce muscular rigidity with a more rapid onset of action than that seen with fentanyl. Skeletal muscle rigidity also has been reported to occur or recur infrequently in the extended postoperative period usually following high dose administration. In addition, skeletal muscle movements of various groups in the extremities, neck, and external eye have been reported during induction of anesthesia with Sufentanil Citrate Injection; these reported movements have, on rare occasions, been strong enough to pose patient management problems.

The incidence of skeletal muscle rigidity can be reduced by: 1) administration of up to 1/4 of the full paralyzing dose of a non-depolarizing neuromuscular blocking agent just prior to administration of sufentanil at dosages of up to 8 mcg/kg, 2) administration of a full paralyzing dose of a neuromuscular blocking agent following loss of consciousness when sufentanil is used in anesthetic dosages (above 8 mcg/kg) titrated by slow intravenous infusion, or, 3) simultaneous administration of sufentanil and a full paralyzing dose of a neuromuscular blocking agent when sufentanil is used in rapidly administered anesthetic dosages (above 8 mcg/kg).

The neuromuscular blocking agents used should be compatible with the patient's cardiovascular status. The hemodynamic effects and degree of skeletal muscle relaxation required should be considered in the selection of a neuromuscular blocking agent. High doses of pancuronium may produce increases in heart rate during sufentanil-oxygen anesthesia. Bradycardia and hypotension have been reported with other muscle relaxants during sufentanil-oxygen anesthesia; this effect may be more pronounced in the presence of calcium channel and/or beta-blockers. Muscle relaxants with no clinically significant effect on heart rate (at recommended doses) would not counteract the vagotonic effect of sufentanil, therefore a lower heart rate would be expected. Rare reports of bradycardia associated with the concomitant use of succinylcholine and sufentanil have been reported.
The most common symptom after an inguinal hernia is postoperative pain. According to the severity of the pain, the quality of life of the patient is also affected. There are many factors associated with postoperative pain. In the literature, there are factors whose relationship could not be determined clearly in the guidelines prepared for this. A meta-analysis showed that TAPP was associated with less chronic pain than open hernia repair. In another study, it was reported that hernia size and type were unrelated to pain. In the same study, the relationship between preoperative pain and postoperative pain was examined. Etele et al. reported that mesh fixation may increase pain. It is thought that the determination of these multiple predictive factors will both guide postoperative pain management and strengthen patient communication. As a result of the research, it is planned to obtain results related to the factors affecting the postoperative pain.
FIELD: hair care facilities. SUBSTANCE: spherical applicator is adapted for applying of hair setting means or hair care means immediately onto hair and has balloon closed at one end with movable rotating locking member, and locking member holder. Balloon comprises hair composition free of surfactant with carboxyl groups and including, in cosmetically compatible medium, at least one compound selected in the group consisting of anionic, amphoteric, non-ionic fixing polymers; components adapted for improvement of cosmetic qualities of hair or appearance thereof and selected from the group consisting of synthetic, mineral or vegetable oils, fluorinated or perfluorinated oils, natural or synthetic waxes, silicones, cationic polymers, ceramide-type compounds, cationic surfactants, fatty amines, fatty acids and derivatives thereof, fatty alcohols and derivatives thereof; hair dyes. Compound is applied to hair for providing fixation of hairdo and/or for producing of favorable effect upon cosmetic state of hair and/or glossing thereof. EFFECT: increased efficiency by providing localized and precise applying of cosmetic hair care means from one tress to another. 17 cl, 6 ex
333369EPY3004 is the open-label extension study that follows the double-blind studies 333369EPY3001 and 333369EPY3002 (NCT00425282 and NCT00433667, respectively). In an open label study such as 333369EPY3004, both the physician and the patient know the name of the assigned study medication. In a double blind study such as 333369EPY3001 and 333369EPY3002, neither the physician nor the patient knows the name of the assigned study medication. Patients who complete the double-blind treatment phase of studies 333369EPY3001 and 333369EPY3002 will be eligible to enter the open-label extension study 333369EPY3004 during which patients will transition through a blinded period to an open-label period with carisbamate (also referred to as RWJ-333369). There will be a blinded transition during which patients will take blinded study medication; after this, patients will then take unblinded, open-label study medication. No patients will receive placebo during the open-label extension. Safety assessments include the monitoring of the frequency, severity, and timing of adverse events, clinical laboratory test results, 12-lead electrocardiogram (ECG) recordings, vital signs measurements, physical and neurologic examinations, the Physician Withdrawal Checklist for symptoms of withdrawal for those patients who taper and/or discontinue study drug, and pregnancy tests for females of childbearing potential. Seizure counts will be obtained at every visit. A Quality of Life in Epilepsy questionnaire will be administered during the study. There is no statistical testing hypothesis for this study. Detailed Description update,5 Oct 2009. The Sponsor in conjunction with the DSMB agreed to amend the protocol to withdraw patients who develop signs of a drug hypersensitivity reaction. Open-label treatment with carisbamate 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses BID for up to 1 year; study drug should be swallowed whole and not be chewed, divided, crushed, or dissolved.
The invention relates to bamboo charcoal handmade soap and a preparation technology thereof. The bamboo charcoal handmade soap comprises a formula main ingredient and a formula auxiliary ingredient. The formula main ingredient comprises the following components in percentages by mass: 85-97% of a vegetable oil soap base and 1-10% of bamboo charcoal powder. The formula auxiliary ingredient comprises the following components in percentages by mass: 1-5% of bamboo vinegar, 0.1-1.5% of a chamomile extracting solution and 0.01-0.05% of rose essential oil. Formula components of the handmade soap are improved, the addition amounts of the various components are defined, functions of the components are maximized through the simple and feasible preparation technology, on the basis of a deep cleaning function of the bamboo charcoal powder, functions of sterilizing, softening skin, deeply whitening, deeply locking water and the like are fulfilled, furthermore, fat secretion can be balanced, fat is inhibited and acnes are resisted, and tache noire is eliminated. The preparation cost is low.
This prospective un-blinded randomized trial will follow patients with respiratory failure and ALI/ARDS who require invasive mechanical ventilation in select ICUs. Patients will be allocated to respiratory support with either APRV mode or volume control (AC) mode of mechanical ventilation. Qualifying patients will be randomized by permuted block randomization within 24 hours of admission to the ICU. Identical ventilation and oxygenation thresholds will be utilized to guide titration of each ventilator protocol. Patients will remain on the assigned mode of ventilation until they are extubated and discharged from the ICU.

Procedures for treatment evaluation include daily monitoring of the Ventilator protocol in each arm. Clinical coordinator and study respiratory therapist will perform 2 daily checks of the study patients to determine compliance with the protocol and if patient meets weaning criteria. The previously published ARDS Network continuous positive airway pressure (CPAP) weaning protocol will be used for all patients enrolled.
PURPOSE: A composition containing trisindoline is provided to prevent or treat cancer with excellent cytotoxicity to cancer cell line. CONSTITUTION: A composition for preventing or treating cancer contains trisindoline as an active ingredient. The trisindoline has cytotoxicity to multidrug-resistant cancer cell line. A method for manufacturing the trisindoline comprises: a step of preparing cells containing nucleotide encoding indigo-producing oxygenase; a step of culturing cells in a medium; and a step of isolating trisindoline from the culture liquid. An indigo-producing oxygenase is derived from Rhodococcus sp. The indigo-producing oxygenase gene is ipoA gene. The IpoA gene is mutated to produce IpoA protein in which 58th, 59th, or 251th amino acid of sequence number 2 is substituted. The 58th alanine is substituted with serine. The cell is E. coli.
On the first day of the intervention phase, research assistants visited TG's participants to introduce the MAD in the presence of caregivers. After the training session, which lasted 40 min approximately, the MAD was personalized according to the participant's prescriptions and through discussions with them on an appropriate schedule for presenting the reminders. Research assistants used the MAD administrator sub-system to enter the medication names, health problems to address, timetables, and the frequency at which medications should be taken. Then, they attached and configured NFC tags to each of the pill containers, which included selecting the images that best represented the pills and their containers to be used to form the visual reminders. Afterward, the MAD was placed in the homes' area where participants reported taking medications. MAD was used for 5 weeks during which data on medication adherence and system adoption was collected from the TG.
After laparoscopic exploration, HIPEC was started immediately, at least 4 HIPEC was completed.Three to six weeks after HIPEC was completed, chemotherapy was started.The curative effect was evaluated every 2-4 cycles. If the operation standard of R0 was met, the second laparoscopic staging was performed: if the peritoneal metastasis reached P 0 or P1a, the operator judged that R0 could be removed. Open radical gastrectomy (D2 / D2 +) was performed. For P1b / c cases, the original treatment was continued until the disease progressed.
In carcinogenicity studies, lapatinib was administered orally for up to 104 weeks at doses of 75 and 150 mg/kg/day in male mice and 75, 150, and 300 mg/kg/day in female mice (approximately 0.7 to 2 times the expected human clinical exposure based on AUC for a clinical dose of 1,250 mg/day plus capecitabine) and 60, 120, 240, and 500 mg/kg/day (approximately 0.6 to 2.3 times the expected human clinical exposure based on AUC) in male rats, and 20, 60, and 180 mg/kg/day (approximately 1.4 to 10 times the expected human clinical exposure based on AUC for a clinical dose of 1,250 mg/day plus capecitabine) in female rats. There was no evidence of carcinogenicity in mice. In male rats, there was an increased incidence of whole body combined hemangiomas and hemangiosarcomas.

Lapatinib was not clastogenic or mutagenic in the Chinese hamster ovary chromosome aberration assay, microbial mutagenesis (Ames) assay, human peripheral lymphocyte chromosome aberration assay or the in vivo rat bone marrow chromosome aberration assay at single doses up to 2,000 mg/kg.

There were no effects on male or female rat mating or fertility at doses up to 120 mg/kg/day in females and 180 mg/kg/day in males (approximately 6.4 times and 2.6 times the expected human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine, respectively). The effect of lapatinib on human fertility is unknown. However, when female rats were given oral doses of lapatinib during breeding and through the first 6 days of gestation, a significant decrease in the number of live fetuses was seen at 120 mg/kg/day and in the fetal body weights at greater than or equal to 60 mg/kg/day (approximately 6.4 times and 3.3 times the expected human clinical exposure based on AUC following 1,250 mg dose of lapatinib plus capecitabine, respectively).
PURPOSE:To obtain a cosmetic having an excellent whitening activity for skins from the extract of an animal or plant which has been used as a folk medicine, a Chinese medicine or a cosmetic except the whitening cosmetic and whose safety has been guaranteed. CONSTITUTION:A whitening cosmetic having the above-mentioned activity contains one kind or more of extracts in an dry amount of 0.0001-10wt.%, preferably 0.0005-3wt.%, the extracts being obtained by extracting Quercusstenphylla leaves, KAIBO (the bulb of Fritillaria thunbergii) or AKO (a glue) with a mixture of water with a hydrophilic organic solvent such as ethanol, methanol, acetone, propylene glycol, glycerol or 1,3-butylene glycol. The Quercusstenphylla leaves of the raw material are a folk medicine peculiar to Japan and are applied to cholecystitis and nephrolithiasis, and the KAIBO is known to have pharmacological activities such as antitussive, expectorant and antipyretic activities. But both the ingredients are not known as cosmetics. Further, the AKO is used as a hemostatic agent or a clathrating agent, but is not known as a whitening agent. Since the ingredients have been used as folk medicines, galenicals or other cosmetics, the safety of the ingredients are guaranteed.
The present invention provides a novel compound having a superior Na<+> channel inhibitory activity. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them.In the formula, the ring A represents a ring represented by the formula:(wherein R<1 >represents a hydrogen atom etc.; and R<2 >represents indicates a hydrogen atom and the like) etc.; W represents an optionally substituted C1-6 alkylene group etc.; Z represents an optionally substituted C6-14 aromatic hydrocarbon cyclic group etc.; and l represents an integer from 0 to 6.
<P>PROBLEM TO BE SOLVED: To provide a medical support system that implements electronic medical record management, order management, work schedule management and the like by means of a portable terminal usable inside and outside a medical facility and having a voice call function, a data communication function, a hands-free function, a personal authentication function and the like.  <P>SOLUTION: The medical support system comprises a medical facility management apparatus 3 connected to an external network 21 and an internal network 22, and the portable terminal 6 enabling communication with the medical facility management apparatus 3 via the external network 21 or internal network 22. The portable terminal comprises an input means, an output means, a communication means, a storage means, a processing means and a voice conversion means. The communication means switches a communication system for communication by determining whether or not the internal network 22 is accessible. The processing means, at power input, compares biometric information input by a portable terminal holder from the input means with biometric information recorded on the storage means, and if they match, starts a power supply.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
NEW MATERIAL:A macrocyclic alcohol derivative shown by formula VIII (R is H or phenylthio). USE:A drug. The macrocyclic alcohol derivative shown by formula VIII is a derivative of sarcophytol A or B and is expected to be useful as a carcinogensis inhibitor. PREPARATION:An allyl alcohol shown by formula I and a dimethylacetal shown by formula II are subjected to Claisen rearrangement to form a gamma,delta-unsaturated ketone shown by formula III, which is reduced with NaBH4, etc., to give an alcohol derivative, a mixture of diastereomer. OH group of this alcohol derivative which is not separated is protected, the benzoate is hydrolyzed into a mesylate, which is further converted into a hydroxymonomesylate. The hydroxymonomesylate is reacted in methanol in the presence of K2CO3 to give epoxy derivatives shown by formula IV and formula V. These derivatives are reacted with 1,4-diazabicyclo[2,2,2]octane in the presence of n-butyllithium to give a compound shown by formula VIII, a compound shown by formula VI or formula VII.
Images will be obtained both before and after intravenous bolus injection with subsequent dynamic imaging. Dynamic contrast enhancement maps will be created for evaluation of residual tumor. Images will be reformatted into three orthogonal planes as well as into a 3D model for surgical orientation. All imaging protocols using contrast, contrast enhancement maps and reformatting, as described above, which will be applied to the intra-operative MRI performed in the AMIGO suite are consistent with the standard MRI breast imaging at Brigham and Women's Hospital.
This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
Experimental research design with two-group repeated-measure design. The investigators estimate there are recruit fifty patients from related rehabilitation hospital of a medical center in Taichung, central Taiwan, using randomization put patients in experimental group and control group. Experimental group Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail. Control group was pressing sham ponits. Research tools to self semi-structured questionnaire collected data on patient's diet, activity, medication, defecation patterns, subjective defecation feelings, and auscultation bowel sounds like. The investigators expected the results of this study can provide clinical nursing care for stroke patients of reference, to improve quality of care, and increase acupressure to improve the empirical data of stroke in patients with constipation.